Long-Term Survivorship and Quality of Life After Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

2003 ◽  
Vol 10 (2) ◽  
pp. 155-162 ◽  
Author(s):  
Richard P. McQuellon ◽  
Brian W. Loggie ◽  
Anna B. Lehman ◽  
Gregory B. Russell ◽  
Ronald A. Fleming ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Carcinomatosis ◽  
Cytoreductive Surgery ◽  
Intraperitoneal Hyperthermic Chemotherapy ◽  
Hyperthermic Chemotherapy

Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis

2001 ◽  
Vol 27 (1) ◽  
pp. 65-73 ◽  
Author(s):  
R.P. McQuellon ◽  
B.W. Loggie ◽  
R.A. Fleming ◽  
G.B. Russell ◽  
A.B. Lehman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Hyperthermic Chemotherapy ◽  
Hyperthermic Chemotherapy

scholarly journals Survival and Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colonic Origin

2011 ◽  
Vol 18 (13) ◽  
pp. 3673-3679 ◽  
Author(s):  
Adrienne R. Hill ◽  
Richard P. McQuellon ◽  
Gregory B. Russell ◽  
Perry Shen ◽  
John H. Stewart ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Carcinomatosis ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy

scholarly journals The impact of hyperthermic intraperitoneal chemotherapy and cytoreductive surgery on clinical outcomes and quality of life of patients with peritoneal carcinomatosis

2021 ◽  
Author(s):  
Oleksandr Vadymovych Bondar ◽  
Serhii Hennadiiovych Chetverikov ◽  
Viacheslav Yevheniiovych Maksymovskyi ◽  
Dmytro Vadymovych Atanasov ◽  
Valeriia Volodymyrivna Chetverikova-Ovchynnyk ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Peritoneal Carcinomatosis ◽  
Clinical Outcomes ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
The Impact

Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis

2007 ◽  
Vol 14 (3) ◽  
pp. 1105-1113 ◽  
Author(s):  
Richard P. McQuellon ◽  
Suzanne C. Danhauer ◽  
Gregory B. Russell ◽  
Perry Shen ◽  
Joyce Fenstermaker ◽  
...  
Keyword(s):  
Health Outcomes ◽  
Peritoneal Carcinomatosis ◽  
Cytoreductive Surgery ◽  
Intraperitoneal Hyperthermic Chemotherapy ◽  
Hyperthermic Chemotherapy

Predictors of complications after cytoreductive surgery associated with HIPEC in the treatment of peritoneal carcinomatosis.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14119-e14119
Author(s):  
Fabio Oliveira Ferreira ◽  
Samuel Aguiar ◽  
Alessandro Lima ◽  
Erika Maria Monteiro Santos ◽  
Wilson Toshihiko Nakagawa ◽  
...  
Keyword(s):  
Postoperative Complications ◽  
Peritoneal Carcinomatosis ◽  
Cytoreductive Surgery ◽  
Rating Scales ◽  
Postoperative Mortality ◽  
Intraperitoneal Hyperthermic Chemotherapy ◽  
Asa Classification ◽  
Hyperthermic Chemotherapy ◽  
Select Group ◽  
Duration Of Surgery

e14119 Background: A select group of patients with peritoneal carcinomatosis (PC) has been treated with curative intent by cytoreductive surgery (CCS) associated with intraperitoneal hyperthermic chemotherapy (HIPEC). The objective of this study is to identify predictors of postoperative complications in patients undergoing CCS + HIPEC. Methods: We analyzed data from 136 procedures of CCS + HIPEC in 128 patients with PC, from March 2001 to December 2010. Variables clinical, surgical, and the scores obtained by rating scales of risk (ASA, POSSUM and ACE-27), were correlated with scores obtained by rating scales of morbidity and postoperative results (Bennett-Guerrero, NCI and McPeek). Carcinomatosis was caused by tumors of the appendix in 54 cases (39.7%), ovary in 43 (31.6%), colorectal in 22 (16.2%), peritoneal mesothelioma in 14 (10.3%) and others in three (2.2%). All patients were classified as ECOG 0 and 1 and had KPS> 80%. Complete cytoreduction (CC0) was performed in 93 (68.4%), CC1 30 (22.1%) and CC2 or CC3 in 13 (9.5%). Results: The rates of OS and the median follow-up were respectively 79.6% and 102 months for patients with CP of origin in tumors of the appendix, 78.6% and 74.8 months for source of peritoneal mesotheliomas, 73,9% and 55.9 months for ovarian origin and 36.4% and 31.1 months for colorectal origin. The morbidity (serious complications NCI - grade 3, 4, and 5) and postoperative mortality (30 days) were respectively 16.9% and 2.9%. The duration of surgery (> 9 hours) and ASA classification Scale (ASA class III) were the main predictors of postoperative complications in multivariate analysis. Age was a predictor of cardiovascular complications and one of the variables responsible for longer ICU stay. The number of anastomoses performed per procedure (2 or 3) was associated with the occurrence of infectious complications systemic and wound. Conclusions: The duration of surgery, ASA classification in scale, age and number of anastomoses were the factors most often related to the occurrence of severe postoperative complications after cytoreductive surgery associated with intraperitoneal hyperthermic chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document